Hyperuricemia
-
Subject Areas on Research
- CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
- Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
- Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
- Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
- Dietary and commercialized fructose: Sweet or sour?
- Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
- Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
- Febuxostat: a new agent for lowering serum urate.
- Genetics of hyperuricemia and gout: implications for the present and future.
- Gout and its comorbidities.
- Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
- Hyperuricemia, gout, and cardiovascular disease--an important "muddle".
- Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
- Normal glycine-C14-incorporation into uric acid in primary gout.
- On the mechanism of overproduction of uric acid in patients with primary gout.
- Overproduction of uric acid as the cause of hyperuricemia in primary gout.
- Progress in the pharmacotherapy of gout.
- Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
- Safety of urate-lowering therapies: managing the risks to gain the benefits.
- The current state of care in gout: Addressing the need for better understanding of an ancient disease.
- Update on the management of hyperuricemia and gout.
- Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure.
- Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
-
Keywords of People
- O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology